Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: Insights from the Everest (efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan) trial

Journal of the American College of Cardiology

Volumn 61, Issue 5, 2013, Pages 571-579

  Butler, Javed ^a   Subacius, Haris ^b   Vaduganathan, Muthiah ^c   Fonarow, Gregg C ^d   Ambrosy, Andrew P ^e   Konstam, Marvin A ^f   Maggioni, Aldo ^g   Mentz, Robert J ^h   Swedberg, Karl ⁱ   Zannad, Faiez ^j   Gheorghiade, Mihai ^b  

^a EMORY UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ANMCO RESEARCH CENTER   (Italy)

^h DUKE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j INSERM   (France)

more..

Author keywords

acute heart failure; clinical trials; outcomes assessment; quality of care

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; NITRIC ACID DERIVATIVE; PLACEBO; TOLVAPTAN;

ACUTE HEART FAILURE; ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMORBIDITY; COMPARATIVE STUDY; DRUG EFFICACY; EASTERN EUROPE; FEMALE; FOLLOW UP; GEOGRAPHICAL DIFFERENCE; GEOGRAPHY; HEART EJECTION FRACTION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NORTH AMERICA; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; SAMPLE SIZE; SEX DIFFERENCE; SOUTH AMERICA; WESTERN EUROPE;

AGED; AGED, 80 AND OVER; BENZAZEPINES; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; EUROPE; EUROPE, EASTERN; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; NORTH AMERICA; PATIENT SELECTION; PROSPECTIVE STUDIES; SOUTH AMERICA; SURVIVAL RATE; TREATMENT OUTCOME; VASOPRESSINS;

EID: 84873095762     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.10.025     Document Type: Article

References (23)

1. D. Lloyd-Jones, R.J. Adams, T.M. Brown Heart disease and stroke statistics-2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
2. J. Chen, S.L. Normand, Y. Wang, H.M. Krumholz National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008 JAMA 306 2011 1669 1678
3. M. Gheorghiade, M.A. Konstam, J.C. Burnett Jr. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 2007 1332 1343
4. P.S. Pang, M. Gheorghiade A review of phase II acute heart failure syndromes clinical trials Heart Fail Clin 7 2011 441 450
5. M. Gheorghiade, F. Zannad, G. Sopko Acute heart failure syndromes: current state and framework for future research Circulation 112 2005 3958 3968
6. M. Gheorghiade, P.S. Pang, C.M. O'Connor Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase Am Heart J 161 2011 224 232
7. S.P. Collins, P.S. Pang, C.J. Lindsell International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes Eur J Heart Fail 12 2010 1253 1260
8. B.M. Massie, J.G. Cleland, P.W. Armstrong Regional differences in the characteristics and treatment of patients participating in an international heart failure trial The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators J Card Fail 4 1998 3 8
9. B. Pitt, F. Zannad, M. Gheorghiade Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHESUS trial Int J Cardiol 143 2010 309 316
10. J.E. Blair, F. Zannad, M.A. Konstam Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program J Am Coll Cardiol 52 2008 1640 1648
11. S.W. Glickman, J.G. McHutchison, E.D. Peterson Ethical and scientific implications of the globalization of clinical research N Engl J Med 360 2009 816 823
12. M. Gheorghiade, C. Orlandi, J.C. Burnett Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) J Card Fail 11 2005 260 269
13. M.A. Konstam, M. Gheorghiade, J.C. Burnett Jr. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 2007 1319 1331
14. K. Getz Global clinical trials activity in the details Appl Clin Trials September 1, 2007 http://appliedclinicaltrialsonline.findpharma.com/ appliedclinicaltrials/article/articleDetail.jsp?id=453243 Accessed November 23, 2012
15. C. Truelove 21st Annual report: belt tightens on big pharma Med Ad News 26 2007 4 7
16. J.P. Garnier Rebuilding the R&D engine in big pharma Harv Bus Rev 86 2008 68 70 72-6, 128
17. J.A. DiMasi, R.W. Hansen, H.G. Grabowski The price of innovation: new estimates of drug development costs J Health Econ 22 2003 151 185
18. C.M. O'Connor, M. Fiuzat, K. Swedberg Influence of global region on outcomes in heart failure beta-blocker trials J Am Coll Cardiol 58 2011 915 922
19. M.R. Bristow, G.A. Murphy, H. Krause-Steinrauf An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure Circ Heart Fail 3 2010 21 28
20. D.L. Bhatt, P.G. Steg, E.M. Ohman International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 295 2006 180 189
21. D.B. Goldstein, S.K. Tate, S.M. Sisodiya Pharmacogenetics goes genomic Nat Rev Genet 4 2003 937 947
22. H.N. Larson, J. Zhou, Z. Chen, J.S. Stamler, H. Weiner, T.D. Hurley Structural and functional consequences of coenzyme binding to the inactive asian variant of mitochondrial aldehyde dehydrogenase: roles of residues 475 and 487 J Biol Chem 282 2007 12940 12950
23. H.K. Seitz, S. Matsuzaki, A. Yokoyama, N. Homann, S. Vakevainen, X.D. Wang Alcohol and cancer Alcohol Clin Exp Res 25 2001 137S 143S